Clinton/Reid Bill Would Boost Cancer Tracking at CDC

Publication
Article
OncologyONCOLOGY Vol 16 No 8
Volume 16
Issue 8

Now that President Bush has appointed Julie Gerberding to head the Centers for Disease Control and Prevention (CDC), groups like the Trust for America’s Health are urging her to make cancer tracking a priority.

Now that President Bush has appointed Julie Gerberding to head the Centersfor Disease Control and Prevention (CDC), groups like the Trust for America’sHealth are urging her to make cancer tracking a priority. 

A new bill—the Nationwide Health Tracking Act—introduced by Sen. HillaryClinton (D-NY) and Sen. Harry Reid (D-Nev) would authorize $227.5 million a yearfor expansion of a pilot CDC chronic disease tracking program. The Clinton/Reidbill, which has a counterpart in the House, grew out of hearings held in Fallon,Nev, and Long Island, NY, that focused on possible environmental links to cancerin those communities. 

Congress gave the CDC $17.5 million in fiscal 2002 to help get itsenvironmental health-tracking program off the ground. But at that funding level,the program’s reach is limited. Shelley Hearne, executive director of theTrust, points out that Congress just gave the CDC an extra $1 billion forbioterrorism. "But this funding and the CDC’s guidelines on how to spendit do not help the nation prepare for the number 1 killer of Americans today—chronicdiseases like cancer, asthma, and Parkinson’s disease," she states.

Recent Videos
Treatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.
Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.
Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.